β-Blocker effects in huntington's disease : A caution on clinical interpretation
A recent retrospective analysis of Enroll HD data suggesting β-blockers slow Huntington's disease progression has triggered patient demand but requires caution. The findings rely solely on small observational subsets and are vulnerable to bias and confounding. A prior Mendelian-randomization study found no causal link between β-blockers and HD onset; instead, genetically higher blood pressure was
